Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings estimates for Immunic in a research note issued on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now expects that the ...

Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Nurix Therapeutics (NRIX – Research Report) on April 2. The company’s ...

In a report released on April 1, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

Equities researchers at Leerink Partnrs reduced their FY2027 EPS estimates for shares of McKesson in a research note issued ...

As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. Analyst Price Forecast Suggests 419.11% Upside ...

Leerink lowered the firm’s price target on AirSculpt Technologies (AIRS) to $2.50 from $6.50 and keeps a Market Perform rating on the shares. Q4 results featured a continuation of challenges around ...

But the deal amount still came 41% below Leerink Partners’ $487 million valuation for 2seventy based on the biotech’s expected future cash flows. Before ending its coverage of 2seventy at the ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink Partners analysts said that the risks from Trump’s tariffs on the biopharma ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...